stockrowProgyny, Inc.
PGNY Healthcare Healthcare Plans
Progyny, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 10.4% from fiscal 2024.
- Revenue
- +8.91%
- EPS
- +115.3%
- Free cash flow
- +2.72%
Quarter to September 2026, against a year earlier
Follow PGNY
Alert me
Progyny, Inc. (PGNY) Total debt
Progyny, Inc.'s total debt at the end of fiscal 2022 was $7.7M, down 10.8% from $8.7M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $19.5M. Over the past ten years it has ranged from $253.0K (fiscal 2018) to $8.7M (fiscal 2021); the current reading is higher than 60% of that period. Progyny, Inc. ranks 10th of 12 Healthcare Plans companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $7.7M | (10.83%) |
| FY2021 | $8.7M | 3.99% |
| FY2020 | $8.3M | 3,187.75% |
| FY2018 | $253.0K | (95.12%) |
| FY2017 | $5.2M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $19.5M | (0.51%) |
| Jun 2023 | $19.6M | (0.50%) |
| Mar 2023 | $19.7M | 155.24% |
| Dec 2022 | $7.7M | 14.78% |
| 11 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| CI Cigna Group compare | $31.1B |
| ELV Elevance Health, Inc. compare | $30.8B |
| CNC Centene Corporation compare | $15.5B |
| HUM Humana Inc. compare | $12.5B |
| MOH Molina Healthcare, Inc compare | $4.0B |
| OSCR Oscar Health, Inc. compare | $432.4M |
| ALHC Alignment Healthcare, Inc. compare | $324.5M |
| PGNY Progyny, Inc. | $19.5M |
| CLOV Clover Health Investments, Corp. compare | $1.4M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on PGNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement